FGFR2 and cholangiocarcinoma: Notably, patients with FGFR2 fusion transcript cases and those with an FGFR2 mutation showed dramatic responses to therapeutic FGFR inhibition, consistent with other reported favorable results targeting FGFR mutations/fusions in advanced CCA [58,64,65].